Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 256 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the sale, the insider now owns 111,891 shares in the company, valued at approximately $13,434,752.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Natera Trading Down 1.1 %

Shares of NASDAQ:NTRA opened at $118.65 on Thursday. The company’s 50-day moving average price is $123.43 and its two-hundred day moving average price is $111.03. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a market capitalization of $14.57 billion, a PE ratio of -38.03 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period in the previous year, the business earned ($0.97) EPS. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, equities analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera in the 2nd quarter valued at $28,000. Quarry LP grew its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares during the period. Tobam acquired a new stake in Natera in the second quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in Natera during the 1st quarter worth about $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of recent research reports. Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. BTIG Research upped their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. TD Cowen lifted their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Leerink Partners boosted their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.